Sector News

Mylan said to be eyeing a $7B-plus bid for rising star Hikma

January 29, 2015
Life sciences
Hikma Pharmaceuticals is no stranger to buyout rumors. The Jordan-based drugmaker pops up often in deal talk, partly because of its sales and infrastructure in emerging markets. Now, there’s another reason or two–its recent win on the gout drug Mitigare and its impending entry onto London’s Financial Times Stock Exchange. New rumors, too.
 
Hikma shares were up in London today on talk of a potential sale to Mylan, the U.S.-based generics maker, according to a brief in The Independent. Meanwhile, This is Money put up Big Biotech leader Amgen as a possibility.
 
The price would be richer than it would have been several weeks ago, because Hikma shares hit an all-time high of £25 earlier this month. The company’s market cap is now about £4.7 billion, This is Money figures–almost at the £5 billion threshold founding family member Samih Darwazah has pegged as a potential sale point for the company.
 
The Independent’s rumors put a Mylan bid at £35 per share–and the talk was sufficiently hot to persuade Evercore ISI analyst Umer Raffat to issue a note about potential cost synergies and earnings growth associated with a Mylan-Hikma combo. Raffat figures the 25% to 35% in SG&A and R&D costs could be squeezed out after a takeover, with earnings accretion of $0.12 this year and $0.25 next, or a 3% to 5% bump.
 
Of course, the Mylan buyout idea has surfaced before, including last year, when investors started to worry that Mylan hadn’t been doing enough deals.
 
Here’s why now might be the time for a Hikma buy: The company prevailed in its long quest to launch Mitigare, a gout drug whose active ingredient is the ancient remedy colchicine.
 
Japan’s Takeda Pharmaceutical had been marketing its own version of colchicine, Colcrys, under an exclusivity granted by FDA in return for putting the widely used–but not FDA-approved–drug through clinical trials.
 
Hikma’s colchicine drug was one of those forced off the U.S. market when the FDA gave Colcrys its blessing. But Hikma persisted with the agency, and last September, the agency blessed Mitigare for launch. Takeda sued the FDA and a U.S. judge put a hold on Mitigare’s launch at first, but then denied the company’s request for an injunction. By early January, Hikma was preparing to roll out Mitigare.
 
Colchicine sales amounted to $688 million in the U.S. for the 12 months ended August 2014, Hikma says. That’s a solid market opportunity for a bigger drugmaker looking for new products to beef up a portfolio.
 
By Tracy Staton
 

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach